Skip to main content

Precigen Inc (PGEN) Stock

Precigen Inc Stock Details, Movements and Public Alerts

Stock Details

Precigen Inc (PGEN), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $3.95. Over the past 52 weeks, it has ranged between $0.65 and $5.22. This places the current price at 75.7% of its 52-week high and 506.8% above its 52-week low. Recent trading volume was recorded at 3,371,191. The 14-day Relative Strength Index (RSI) stands at 57.57, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $3.86 by 2.33%. Similarly, it is above its 200-day moving average of $2.17 by 82.03%. The MACD histogram is 0.05, indicating bullish momentum (MACD Line: 0.17, Signal Line: 0.13).

52-Week Range

$5.22 - $0.65

-24.33% from high · +506.76% from low

Avg Daily Volume

4,730,934

20-day average

100-day avg: 6,836,321

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

9.14

Price to Book

7.25

EV/EBITDA

-3.31

EPS (TTM)

-$0.41

Price to Sales

329.33

Beta

1.61

More volatile than market

How is PGEN valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is PGEN's risk profile compared to the market?
With a beta of 1.61, Precigen Inc is significantly more volatile than the market. For every 10% market move, this stock tends to move 16% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 7.25 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

-3254.00%

EBITDA

$-91,858,000

Return on Equity

-668.00%

Return on Assets

-67.40%

Revenue Growth (YoY)

19.40%

Earnings Growth (YoY)

0.00%

How profitable and efficient is PGEN's business model?
0 The operating margin of -3254.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -668.00% and ROA at -67.40%, the company achieves moderate returns on invested capital.
What are PGEN's recent growth trends?
Precigen Inc's revenue grew by 19.40% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$1.4B

Revenue (TTM)

$4.34M

Revenue/Share (TTM)

$0.02

Shares Outstanding

352.91M

Book Value/Share

-$0.12

Asset Type

Common Stock

What is PGEN's market capitalization and position?
Precigen Inc has a market capitalization of $1.4B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 352.91M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
How does PGEN's price compare to its book value?
Precigen Inc's book value per share is -$0.12, while the current stock price is $3.95, resulting in a price-to-book (P/B) ratio of -32.11. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$8.25

108.86% upside potential

Analyst Recommendations

Strong Buy

2

Buy

1

Hold

1

Sell

0

Strong Sell

0

How reliable are analyst predictions for PGEN?
4 analysts cover PGEN with 75% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $8.25 implies 108.9% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on PGEN?
Current analyst recommendations:2 Strong Buy, 1 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Nov 1, 2025, 02:31 AM

Technical Indicators

RSI (14-day)

57.57

Neutral

50-Day Moving Average

$3.86

2.33% above MA-50

200-Day Moving Average

$2.17

82.03% above MA-200

MACD Line

0.17

MACD Signal

0.13

MACD Histogram

0.05

Bullish

What does PGEN's RSI value tell investors?
The RSI (Relative Strength Index) for PGEN is currently 57.57, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret PGEN's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.17 above the signal line at 0.13, with histogram at 0.05. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($3.86) is above the 200-day MA ($2.17), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Oct 31, 2025, 12:31 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for PGEN and get notified when the price changes.

Stay Ahead of the Market with Precigen Inc Alerts

Set up price alerts for Precigen Inc and get notified instantly when the price hits your target. Never miss an important price movement again.